

REPORT DOCUMENTATION PAGE

AD-A280 345



Public reporting burden for this report is estimated to average 1 hour per response, including the gathering of information, reviewing existing data sources, gathering and maintaining the data needed, completing and reviewing the report form, collecting and reviewing the information, and completing and reviewing the report form. Send comments regarding this burden estimate or any aspect of this report form, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Project, Washington, DC 20503.

1. AGENCY USE ONLY (leave blank) 2. REPORT DATE **28 Dec 93** 3. REPORT TYPE AND DATES COVERED **Reprint**

4. TITLE AND SUBTITLE
Expression of LINE-1 Retrotransposons in Human Breast Cancer
 MIPR No. **93MM3508**

6. AUTHOR(S)
**Gary L. Bratthauer, B.A., M.T. (A.S.C.P.)
 Robert D. Cardiff, M.D., Ph.D.
 Thomas G. Fanning, Ph.D.**

7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)
**Armed Forces Institute of Pathology
 Department of Cellular Pathology
 Washington, DC 20306-6000**

**DTIC ELECTRIC
 JUN 13 1984
 S G D**

9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES)
**U.S. Army Medical Research, Development,
 Acquisition and Logistics Command (Provisional)
 Fort Detrick
 Frederick, Maryland 21702-5012**

10. SPONSORING/MONITORING AGENCY REPORT NUMBER

11. SUPPLEMENTARY NOTES
Title of MIPR: Role of LINE-1 Retrotransposons in Human Breast Cancer

12a. DISTRIBUTION/AVAILABILITY STATEMENT
Approved for public release; distribution unlimited

12b. DISTRIBUTION CODE

13. ABSTRACT (Maximum 200 words)

Several diseases have been linked to the insertion of human LINE-1 retrotransposons (L1s) into structural genes. Recently, the element has been shown to be expressed in a variety of adult and pediatric germ cell cancers, leading to speculation that L1s-induced insertion mutation may play a role in the etiology of some neoplasias.

DTIC QUALITY INSPECTED 2

14. SUBJECT TERMS
Breast Cancer, Retrotransposon, gene expression, immunohistochemistry, Reprint, RAD VI

15. NUMBER OF PAGES

16. PRICE CODE

17. SECURITY CLASSIFICATION OF REPORT
Unclassified

18. SECURITY CLASSIFICATION OF THIS PAGE
Unclassified

19. SECURITY CLASSIFICATION OF ABSTRACT
Unclassified

20. LIMITATION OF ABSTRACT
Unlimited

94 6 13 074

94-18182

69

Expression of LINE-1 Retrotransposons in Human Breast Cancer

Gary L. Bratthauer, B.A., M.T.(A.S.C.P.),* Robert D. Cardiff, M.D., Ph.D.,†
and Thomas G. Fanning, Ph.D.*

Background. Several diseases have been linked to the insertion of human LINE-1 retrotransposons (L1Hs) into structural genes. Recently, the element has been shown to be expressed in a variety of adult and pediatric germ cell cancers, leading to speculation that L1Hs-induced insertion mutations may play a role in the etiology of some neoplasias.

Methods. An L1Hs-encoded protein (p40) was assayed in breast cancer cell lines by Western blotting and in solid tumors by immunohistochemical staining and Western blotting.

Results. L1Hs retrotransposons are expressed in a significant number of human breast cancers: expression was detected in 7 of 8 malignant cell lines and in 9 of 12 primary infiltrating ductal carcinomas. No expression was detected in two nonmalignant breast epithelial cell lines, five malignant B- or T-cell lines, tissue from a normal breast, a primary breast sarcoma, or a primary medullary carcinoma of the breast.

Conclusions. These results raise the possibility that L1Hs expression may contribute to the origin or progression of some breast cancers. *Cancer* 1994; 73:2333-36.

Key words: breast cancer, retrotransposon, gene expression, immunohistochemistry.

The human genome contains a class of middle repetitive DNA known as long interspersed elements (LINE-1

Homo sapiens [L1Hs]).¹ Most L1Hs elements are truncated and rearranged pseudogenes, but a small number of transcriptionally active elements are also known to exist,² and recently, one of these active elements has been identified and cloned.³ L1Hs elements have been amplified through retrotransposition: L1Hs RNAs are copied into cDNA by an L1Hs-encoded reverse transcriptase and subsequently integrated into the genome at random positions.^{1,2,4} This process can result in mutations when L1Hs cDNA enter structural or regulatory genes, and human diseases that involve the integration of L1Hs elements are known.⁵

Previous results with cell lines suggested that L1Hs expression might occur in some germ cell cancers: an L1Hs-encoded protein (p40) was detected by Western blotting in the teratocarcinoma cell lines NTera2D1 and 2102Ep and in the choriocarcinoma line JEG-3.⁶ Confirming the results with cell lines, high levels of L1Hs expression have been detected in primary and metastatic germ cell tumors by immunohistochemistry, leading to the speculation that L1Hs is involved in some germ cell neoplasias.^{7,8}

The finding of an L1Hs element inserted de novo into a *myc* allele in a primary breast carcinoma⁹ and into the APC tumor suppressor gene in a colorectal cancer¹⁰ suggests that L1Hs elements are active in cancers other than germ cell cancers. However, these were single, isolated cases and they provide no information concerning the incidence of L1Hs expression in non-germ cell cancers. With this in mind, we have examined a number of breast cancers for L1Hs expression. In the current study, we found that L1Hs is expressed in a significant proportion of solid breast tumors and in cell lines derived from breast tumors.

Materials and Methods

Breast cell lines were obtained from the American Type Culture Collection (Rockville, Maryland) and B- and T-cell lines from G. Heidecker (National Cancer Institute/National Institutes of Health, Bethesda, MD) or the

From the *Department of Cellular Pathology, Armed Forces Institute of Pathology, Washington, DC; and the †Department of Pathology, School of Medicine, University of California, Davis, California.

Supported by the U.S. Army Medical Research and Development Command (MIPR 93MM3508), the Council for Tobacco Research (No. 3441), and intramural funds of the Armed Forces Institute of Pathology. Opinions expressed in this article are the views of the authors and are not to be construed as representing the views of the Department of the Army or the Department of Defense.

The authors thank J. Lund, L. Young, J. Walls, A. Reid, P. Lloyd, and G. Heidecker for help with cells and tissues.

Address for reprints: Thomas G. Fanning, Ph.D., Department of Cellular Pathology, AFIP, Washington, DC 20306-6000.

Accepted for publication December 28, 1993.




Figure 1. Western blot analysis of tumor cell lines. Lanes 1, 2, and 4 contain total cell extracts from SK-BR-3, T47D, and Ntera2D1, respectively. Lane 3 has markers. The arrow identifies the p40 protein. Bands above the p40 band in the breast tumor lines are not related to the p40 protein, because they are also present using the detection system alone.

American Type Culture Collection. Antibody AH40.1 was prepared against a TrpE-p40 fusion protein as described previously,⁶ and control experiments demonstrated that AH40.1 is specific for the p40 protein.⁶⁻⁸ Gel electrophoresis was performed by standard methods, and proteins (circa 30 μ g/sample) were blotted onto Immobilon-P membranes (Millipore Corp., Bedford, MA). Primary antibody was used routinely at a 1:1000 or 1:2000 dilution, and staining was done with the Vectastain ABC Kit (Vector Labs, Burlingame, CA) or with the enhanced chemiluminescence method (Amersham, Arlington Heights, IL). Immunohistochemical staining of frozen tissue sections was done by a standard peroxidase-antiperoxidase method after first fixing the section with ethanol acetic acid (95:5). Primary antibody (sample 4577) was used routinely at a 1:100 dilution on frozen sections.

Results

L1Hs Expression in Cell Lines

The AH40.1 antibody recognizes the product of the first open reading frame of the L1Hs element, the p40 protein.⁶ Western blot analysis of various cell line extracts

with AH40.1 demonstrated that seven of the lines had detectable amounts of p40 (Fig. 1, lane 1). Blots incubated with preimmune serum or with p40 antiserum that had been preabsorbed with the p40 protein showed no p40 band. Table 1 lists the lines and the relative amounts of p40 protein found in them. These relative amounts were estimated by visually comparing the p40 band present on the blot with a control, Ntera2D1, which is known to express the p40 protein abundantly.⁶

Four of the cell lines examined were derived from infiltrating ductal carcinomas, and each had a characteristic amount of p40 ranging from substantial (T47D line) to undetectable (Hs857T line) (Table 1). Thus, there appears to be no correlation between p40 quantity and primary tumor histology, at least for the small number of cell lines we examined.

In addition to the breast tumor lines, we examined two nonmalignant breast epithelial lines and five malignant nonepithelial cell lines of B- or T-cell origin. All were negative for p40 (Table 1). Because none of the malignant nonepithelial tumor lines express L1Hs (Table 1), it appears unlikely that the malignant phenotype alone is sufficient to cause L1Hs expression.

L1Hs Expression in Tumors

To extend the results with the breast tumor lines, we examined 13 primary breast carcinomas by immunocytochemistry and found that 9 were immunoreactive

Table 1. p40 in Human Cell Lines

Cell line	Type	Relative amount p40
Breast		
BT-474	Infiltrating ductal	++
HBL-100	Normal (nonmalignant)	-
Hs587Bst	Normal (nonmalignant)	-
Hs587T	Infiltrating ductal	-
MCF7	Adenocarcinoma	+
MDA-MB-453	Carcinoma	+
MDA-MB-468	Adenocarcinoma	+
SK-BR-3	Adenocarcinoma	+
T47D	Infiltrating ductal	+++
ZR-75-1	Infiltrating ductal	+
Nonepithelial		
AA2	T-cell lymphoma	-
HL-60	Promyelocytic leukemia	-
Hut78	T-cell lymphoma	-
Molt-4	Lymphoblastic leukemia	-
Raji	Burkitt's lymphoma	-




Figure 2. Immunohistochemical staining of an infiltrating ductal carcinoma (tumor N01) with AH40.1 antibody. Tumor tissue was treated with (a) the AH40.1 antibody or (b) preimmune serum and counterstained with hematoxylin (original magnification $\times 400$).

with the AH40.1 antibody (Figs. 2 and 3). All positive cases were infiltrating ductal carcinomas (Table 2). Four breast carcinomas were unreactive with the antibody: three cases were infiltrating ductal carcinomas and one was a medullary carcinoma. Tissues from a normal, noncancerous breast and from a breast sarcoma were also unreactive (Table 2). Preimmune serum was not reactive on the positive cases, nor was p40 antiserum preabsorbed with the p40 protein in those cases that were so tested.

The nine positive cases exhibited various degrees of staining, suggesting that L1Hs expression is variable from tumor to tumor. The results with primary tumors are therefore similar to the results with breast tumor cell lines that also show variability in p40 expression (Table 1).




Figure 3. Western blot analysis of tumor N01. Lane 1: markers; lane 2: Ntera2D1 cell line extract; lane 3: $\frac{1}{5}$ the protein present in lane 2; lanes 4 and 5 are blank; lane 6: N01 tumor extract. The arrow identifies the p40 protein.

Table 2. p40 in Primary Breast Tumors

Tissue	No.	p40+	p40-
Infiltrating ductal	12	9	3
Medullary carcinoma	1	—	1
Sarcoma	1	—	1
Normal breast	1	—	1

To verify further that staining in the primary tumors was due to p40, we extracted protein from a small amount of a tumor designated N01 and performed a Western blot analysis. This tumor was one of the most reactive with the AH40.1 antibody (Fig. 2a), and the results verified that p40 is expressed in tumor N01 (Fig. 3). The sharpness of the p40 band in tumor N01 is interesting, because *in vitro* translation of cloned L1Hs cDNA demonstrated that different L1Hs family members encode p40 proteins with unique mobilities on acrylamide gels.⁶ Thus, it is possible that this solid tumor has only one active class/type of L1Hs element.

Discussion

Breast cancer is one of the most common cancers and is postulated to arise by multistep processes involving the activation of oncogenes and the loss of tumor suppressor genes.^{11,12} Although a number of these steps have been elucidated, many of the events involved in the initiation and maintenance of this cancer are unknown.¹²

Could L1Hs be involved in the initiation or progression of breast cancer or other epithelial cancers? The evidence that it might be consists of the following: (1) a large proportion of certain cancers of epithelial origin contain the L1Hs-encoded p40 protein, (2) normal epithelial cells have no detectable p40, and (3) nonepithelial malignant cells have no detectable p40. The first point demonstrates that L1Hs expression is not a rare event in some cancers (69% for primary breast carcinomas and 88% for breast carcinoma cell lines). The second and third points indicate that L1Hs is not generally expressed in human tissues, be they normal or malignant.

There are several characteristics of the L1Hs element that suggest its potential as an oncogenic agent. One possibility involves the L1Hs-encoded reverse transcriptase. This enzyme may copy cellular RNA (LINEs, SINEs, mRNA) into cDNA, which are subsequently integrated into the genome, leading to the inactivation of important regulatory genes. The inactivation of the APC tumor suppressor gene by *de novo* insertion of an L1Hs element in a colorectal cancer appears to be such an event.¹⁰

Although insertion mutagenesis is the most obvious

mechanism by which L1s might alter cellular metabolism, several additional mechanisms are also possible. Although L1s expression has not been found in normal tissues, many cells appear to contain a DNA-binding protein that may be involved in L1s transcription.¹³ This protein might interact with the L1s internal promoter¹⁴ in neoplastic cells, leading to read-through transcription and activation of genes downstream of the L1s element. In addition, the L1s-encoded p40 protein has a leucine zipper motif,¹⁵ suggesting a possible interaction with other cellular proteins. Such interactions, at inappropriate times, might lead to the disruption of important cellular functions.

The preceding possibilities are only speculation. However, all have been documented with other oncogenes and oncogenic agents.¹⁶ Some major facets of L1s biology to be answered by future research include the influence of abundant p40 expression on cellular metabolism and determination of the ratio between the frequency of L1s expression and the frequency of cDNA insertions into important genes.

References

- Fanning TG, Singer MF. LINE-1: a mammalian transposable element. *Biochim Biophys Acta* 1987; 910:203-12.
- Hutchison CA, Hardies SC, Loeb DD, Shehee WR, Edgell MH. LINEs and related retroposons: long interspersed repeated sequences in the eucaryotic genome. In: Berg DE, Howe MM. *Mobile DNA*. Washington: American Society for Microbiology, 1989:593-636.
- Dombroski BA, Mathias SL, Nanthakumar E, Scott AF, Kazazian HH. Isolation an an active human transposable element. *Science* 1991; 254:1805-8.
- Mathias SL, Scott AF, Kazazian HH, Boeke JD, Gabriel A. Reverse transcriptase encoded by a human transposable element. *Science* 1991; 254:1808-10.
- Kazazian HH, Wong C, Yousoufian H, Scott AF, Phillips DG, Antonarakis S. Hemophilia A resulting from de novo insertion of L1 sequences represents a novel mechanism for mutation in man. *Nature* 1988; 332:164-6.
- Leibold DM, Swergold GW, Singer MF, Thayer RE, Dombroski BA, Fanning TG. Translation of LINE-1 DNA elements in vitro and in human cells. *Proc Natl Acad Sci USA* 1990; 87:6990-4.
- Brathauer GL, Fanning TG. Active LINE-1 retrotransposons in human testicular cancer. *Oncogene* 1992; 7:507-10.
- Brathauer GL, Fanning TG. LINE-1 retrotransposon expression in pediatric germ cell tumors. *Cancer* 1993; 71:2383-86.
- Morse B, Rothberg PG, South VJ, Spandorfer JM, Astrin SM. Insertion mutagenesis of the myc locus by LINE-1 sequences in a human breast carcinoma. *Nature* 1988; 333:87-90.
- Miki Y, Nishisho I, Horii A, Miyoshi Y, Utsunomiya J, Kinzler KW, Vogelstein B, Nakamura Y. Disruption of the APC gene by a retrotransposal insertion of L1 sequence in a colon cancer. *Cancer Res* 1992; 52:643-5.
- Cotran RS, Kumar V, Robbins SL. *Robbins pathologic basis of disease*. 4th ed. Philadelphia: WB Saunders, 1989:239-305.
- Callahan R, Campbell G. Mutations in human breast cancer: an overview. *J Natl Cancer Inst* 1989; 81:1780-6.
- Minakami R, Kurose K, Etoh K, Furuhashi Y, Hattori M, Sakaki Y. Identification of an internal cis-element essential for the human L1 transcription and a nuclear factor(s) binding to the element. *Nucl Acids Res* 1992; 20:3139-45.
- Swergold GD. Identification, characterization, and cell specificity of a human LINE-1 promoter. *Mol Cell Biol* 1990; 10:6718-29.
- Holms SE, Singer MF, Swergold GD. Studies on p40, the leucine zipper motif-containing protein encoded by the first open reading frame of an active human LINE-1 transposable element. *J Biol Chem* 1992; 267:19765-8.
- Bishop JM. Molecular themes in oncogenesis. *Cell* 1991; 64:235-48.

Accession For	
NTIS CRA&I	<input checked="" type="checkbox"/>
DTIC TAB	<input type="checkbox"/>
Unannounced	<input type="checkbox"/>
Justification	
By	
Distribution /	
Availability Codes	
Dist	Avail and/or Special
A-1	20